FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

For years, nuclear imaging – through X rays and more – has helped industries inspect inside equipment without causing damage. However, industrial nuclear imaging has not kept pace with the rapid ...

Findings support clinical application of molecular imaging and use of novel immune cell targeting tracers for development of ...

A macrophage-targeted PET/CT tracer predicts anti-TNF response in rheumatoid arthritis at baseline and four weeks, enabling ...

Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements ...

A preclinical evaluation of a new 'dual-mode' tracer agent shows promise in not only helping surgeons image and plan prostate cancer procedures, but also provide them with much more consistent and ...

A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little as four weeks, and potentially even at the start of treatment, according to new research ...